Mabion (FRA:272) Tariff Resilience Score: 0/10 (As of Jul. 09, 2026)


FRA:272 Mabion SA FRA:272
17 GF Score
Price €1.61
GF Value €0.47
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Mabion Tariff Resilience Score?

Mabion has the Tariff Resilience Score of 0, which implies that the company might have .

Mabion has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Mabion might have .

Mabion  (FRA:272) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Mabion Tariff Resilience Score Related Terms

FRA:272
17GF Score
Mabion SA FRA:272
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mabion (FRA:272) Overvalued in 2026?

Based on GuruFocus' analysis, Mabion stock appears to be overvalued. The current stock price of €1.61 is trading 241.7% above its estimated GF Value™ of €0.47. GuruFocus considers Mabion to be Significantly Overvalued.

Key valuation signals for FRA:272:

  • Tariff Resilience Score: 0
  • GF Value™: €0.47 vs. price of €1.61 (241.7% above fair value)
  • GF Score™: 17/100 with 4 warning signs

No single metric tells the full story. See the FRA:272 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mabion Business Description

Other Exchanges MAB:Poland
Address ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
17GF Score

Get the complete analysis for FRA:272

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.61
Price
€0.47
GF Value